EGFR mutation status (NSCLC actionable)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-EGFR-MUTATION |
|---|---|
| Type | Biomarker |
| Aliases | Статус мутацій EGFR (NSCLC actionable) |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"functional_impact": "Constitutive EGFR signaling activation; T790M confers gefitinib/erlotinib resistance", "gene": "EGFR", "hotspots": ["exon 19 deletion (Δ746-750 most common)", "L858R", "L861Q", "G719X", "S768I", "T790M (resistance)", "exon 20 insertion (variable)"], "type": "activating + resistance"} |
| Measurement | MethodTumor-tissue NGS panel OR ctDNA NGS OR PCR (cobas EGFR Mutation Test) Sensitivity requirementVAF detection threshold ≥1% for ctDNA; tissue more sensitive |
| Related biomarkers | None declared |
Notes
NCCN 2025 mandates universal EGFR testing for advanced non-squamous NSCLC.
Used By
Actionability
BMA-EGFR-C797S-NSCLC- EGFR C797S is the principal acquired resistance mutation to osimertinib. Cis-configuratio...BMA-EGFR-EX19DEL-NSCLC- EGFR exon 19 deletion in advanced NSCLC: osimertinib 1L improves OS vs first-generation E...BMA-EGFR-EX20INS-NSCLC- EGFR exon 20 insertions (excluding A763_Y764insFQEA) are insensitive to classical EGFR-TK...BMA-EGFR-G719X-NSCLC- EGFR exon 18 G719X (G719A/C/S) is an "uncommon" sensitizing mutation (~3% of EGFR-mut NSC...BMA-EGFR-L858R-NSCLC- EGFR L858R in advanced NSCLC: osimertinib 1L is standard (FLAURA); L858R historically sho...BMA-EGFR-MUTATION-GBM- EGFR amplification (~40%) and EGFRvIII variant (~25%) are common in glioblastoma but no t...BMA-EGFR-T790M-NSCLC- EGFR T790M is the dominant acquired-resistance mechanism after 1st/2nd-gen EGFR-TKI (gefi...
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Biomarker
BIO-EGFR-C797S- EGFR C797S resistance mutationBIO-EGFR-EXON19-DELETION- EGFR Exon 19 deletionBIO-EGFR-EXON20-INSERTION- EGFR Exon 20 insertionBIO-EGFR-L858R- EGFR L858R mutationBIO-EGFR-T790M- EGFR T790M (acquired resistance / gatekeeper)BIO-MET- MET alterations (exon 14 skipping or amplification)BIO-MET-AMPLIFICATION- MET amplification (high-level copy-number gain)
Diseases
DIS-HNSCC- Head and neck squamous cell carcinoma (HNSCC)
Indications
IND-NSCLC-2L-DOCETAXEL-RAMUCIRUMAB- IND-NSCLC-2L-DOCETAXEL-RAMUCIRUMABIND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB- IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMABIND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ- IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZIND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL- IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXELIND-NSCLC-3L-OSI-FAILURE-AMI- IND-NSCLC-3L-OSI-FAILURE-AMIIND-NSCLC-ADJUVANT-ATEZO-PDL1POS- IND-NSCLC-ADJUVANT-ATEZO-PDL1POSIND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMO- IND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMOIND-NSCLC-EGFR-1L-AMI-LAZ- IND-NSCLC-EGFR-1L-AMI-LAZIND-NSCLC-EGFR-1L-OSI-CHEMO- IND-NSCLC-EGFR-1L-OSI-CHEMOIND-NSCLC-EGFR-MAINT-OSIMERTINIB- IND-NSCLC-EGFR-MAINT-OSIMERTINIBIND-NSCLC-EGFR-MUT-MET-1L- IND-NSCLC-EGFR-MUT-MET-1LIND-NSCLC-ELDERLY-CARBO-PEM-MOD- IND-NSCLC-ELDERLY-CARBO-PEM-MODIND-NSCLC-PERIOPERATIVE-PEMBRO- IND-NSCLC-PERIOPERATIVE-PEMBROIND-NSCLC-TMB-HIGH-MET-1L-PEMBRO-MONO- IND-NSCLC-TMB-HIGH-MET-1L-PEMBRO-MONO
Questionnaires
QUEST-NSCLC-1L-STUB- Non-small cell lung cancer — first line
Red flag
RF-NSCLC-HIGH-RISK-BIOLOGY- Actionable molecular driver detected (EGFR / ALK / ROS1 / KRAS G12C / BRAF V600E / MET ex...
Tests
TEST-NSCLC-NGS-PANEL- NSCLC comprehensive NGS panel (DNA + RNA fusion)